cbt101
Cell therapyexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 12, 2020 (NCT04557306)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07050316 | Phase 1 | Mar 14, 2025 | Ceres Brain Therapeutics, Eurofins |
| NCT04557306 | Phase 1 | Oct 12, 2020 | CHABiotech CO., Ltd, Cha Medical University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ceres Brain Therapeutics | For profit | 1 | 1 | 1 | 2025 |
| CHABiotech CO., Ltd | For profit | 1 | 1 | 1 | 2020 |
| Cha Medical University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Eurofins | For profit | 1 | 0 | 1 | 2025 |
4 organizations
Page 1 / 1